6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
124 citations
,
January 1996 in “Dermatology” 5 alpha-reductase inhibitors, like finasteride, are used to treat conditions like prostate issues and skin disorders.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
66 citations
,
April 1995 in “The journal of cell biology/The Journal of cell biology” A new protein was made to detect specific skin cell growth receptors and worked in normal skin but not in skin cancer cells.
3 citations
,
February 2023 in “Journal of Investigative Dermatology” Ch55 may help reduce skin scarring and fibrosis.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
2 citations
,
May 2021 in “Research Square (Research Square)” Ketoconazole loaded solid lipid nanoparticles can penetrate skin better than regular drug suspension and marketed product, providing slow, sustained release and improved stability.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
6 citations
,
July 2015 in “Australasian Journal of Dermatology” A man developed an allergic skin reaction after using brimonidine for rosacea.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
July 2015 in “Pharmacological Reports” Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
11 citations
,
July 2023 in “Applied Nanoscience”
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
February 2019 in “International Journal of Dermatology and Clinical Research” Nε-(carboxymethyl) lysine delays hair growth by blocking a key protein.
10 citations
,
December 2024 in “Allergy” Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
January 2022 in “Drugs of Today” 8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
January 2011 in “Reactions Weekly”
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
7 citations
,
October 2015 in “Experimental dermatology” Blocking the mineralocorticoid receptor can help treat skin thinning caused by steroids.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Keyora Lycopene 23 in 1 multi-vitamin improves men's reproductive and metabolic health.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.